These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19571317)

  • 1. ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling.
    Wood AD; Chen E; Donaldson IJ; Hattangadi S; Burke KA; Dawson MA; Miranda-Saavedra D; Lodish HF; Green AR; Göttgens B
    Blood; 2009 Aug; 114(9):1820-30. PubMed ID: 19571317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
    Hexner EO; Serdikoff C; Jan M; Swider CR; Robinson C; Yang S; Angeles T; Emerson SG; Carroll M; Ruggeri B; Dobrzanski P
    Blood; 2008 Jun; 111(12):5663-71. PubMed ID: 17984313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical requirement for Stat5 in a mouse model of polycythemia vera.
    Yan D; Hutchison RE; Mohi G
    Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
    Tong W; Zhang J; Lodish HF
    Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 2A catalytic subunit α (PP2Acα) maintains survival of committed erythroid cells in fetal liver erythropoiesis through the STAT5 pathway.
    Chen W; Gu P; Jiang X; Ruan HB; Li C; Gao X
    Am J Pathol; 2011 May; 178(5):2333-43. PubMed ID: 21514445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
    Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
    Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epo-induced erythroid maturation is dependent on Plcγ1 signaling.
    Schnöder TM; Arreba-Tutusaus P; Griehl I; Bullinger L; Buschbeck M; Lane SW; Döhner K; Plass C; Lipka DB; Heidel FH; Fischer T
    Cell Death Differ; 2015 Jun; 22(6):974-85. PubMed ID: 25394487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
    Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
    Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1.
    Kerenyi MA; Grebien F; Gehart H; Schifrer M; Artaker M; Kovacic B; Beug H; Moriggl R; Müllner EW
    Blood; 2008 Nov; 112(9):3878-88. PubMed ID: 18694996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
    Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M
    Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
    Geron I; Abrahamsson AE; Barroga CF; Kavalerchik E; Gotlib J; Hood JD; Durocher J; Mak CC; Noronha G; Soll RM; Tefferi A; Kaushansky K; Jamieson CH
    Cancer Cell; 2008 Apr; 13(4):321-30. PubMed ID: 18394555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
    Falchi M; Varricchio L; Martelli F; Marra M; Picconi O; Tafuri A; Girelli G; Uversky VN; Migliaccio AR
    Exp Hematol; 2017 Jun; 50():53-76. PubMed ID: 28232234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
    Shi J; Yuan B; Hu W; Lodish H
    Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.
    Ma AC; Fan A; Ward AC; Liongue C; Lewis RS; Cheng SH; Chan PK; Yip SF; Liang R; Leung AY
    Exp Hematol; 2009 Dec; 37(12):1379-1386.e4. PubMed ID: 19772888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
    Quentmeier H; Geffers R; Jost E; Macleod RA; Nagel S; Röhrs S; Romani J; Scherr M; Zaborski M; Drexler HG
    Leukemia; 2008 Dec; 22(12):2169-75. PubMed ID: 18769447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.